Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12V”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05585320
What this trial is testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more
Immuneering Corporation 209
Testing effectiveness (Phase 2)Looking for participantsNCT04146298
What this trial is testing

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Who this might be right for
Pancreatic CancerPancreatic NeoplasmsPancreatic Ductal Adenocarcinoma+1 more
Changhai Hospital 30
Early research (Phase 1)Not Yet RecruitingNCT06545201
What this trial is testing

RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

Who this might be right for
KRAS G12VT Cell Therapy
Henan Cancer Hospital 30
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Not applicableTemporarily Not AvailableNCT05389514
What this trial is testing

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Who this might be right for
KRAS G12V Mutant Advanced Epithelial Cancers
Providence Health & Services
Early research (Phase 1)Active Not RecruitingNCT05631899
What this trial is testing

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumor, AdultEphA2 OverexpressionKRAS G12V+2 more
Chinese PLA General Hospital 9
Early research (Phase 1)Looking for participantsNCT06487377
What this trial is testing

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

Who this might be right for
Pancreatic CancerColorectal Cancer
Shanghai Pudong Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT03190941
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Pancreatic CancerGastric CancerGastrointestinal Cancer+2 more
National Cancer Institute (NCI) 110
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Early research (Phase 1)Active Not RecruitingNCT03875820
What this trial is testing

Phase I Trial of Defactinib and VS-6766.

Who this might be right for
NSCLCLow Grade Serous Ovarian CancerEndometrioid Carcinoma+1 more
Institute of Cancer Research, United Kingdom 87
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105021
What this trial is testing

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-Small Cell Lung CancerColorectal Cancer+2 more
Affini-T Therapeutics, Inc. 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Early research (Phase 1)Active Not RecruitingNCT06767046
What this trial is testing

KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Who this might be right for
ColorectalPancreaticNon-small Cell Lung Cancer (NSCLC)
Corregene Biotechnology Co., Ltd 8
Not applicableAvailableNCT07083479
What this trial is testing

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal AdenocarcinomaKRAS G12DKRAS G12V+12 more
Elicio Therapeutics
Very early researchNot Yet RecruitingNCT07342738
What this trial is testing

TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Who this might be right for
KRAS G12VKRAS G12DSolid Tumor
Sun Yat-sen University 25
Early research (Phase 1)Looking for participantsNCT07349537
What this trial is testing

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Adenocarcinoma+7 more
Revolution Medicines, Inc. 574
Testing effectiveness (Phase 2)Looking for participantsNCT06973564
What this trial is testing

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Who this might be right for
Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd. 294
Testing effectiveness (Phase 2)WithdrawnNCT06690281
What this trial is testing

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Who this might be right for
Gastrointestinal CarcinomaPancreatic CancerHepatocellular Cancer+5 more
National Cancer Institute (NCI)
Load More Results